These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 30972646)

  • 1. Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy.
    Yeo F; Ng CC; Loh KWJ; Molassiotis A; Cheng HL; Au JSK; Leung KT; Li YC; Wong KH; Suen L; Chan CW; Yorke J; Farrell C; Bandla A; Ang E; Lopez V; Sundar R; Chan A
    Support Care Cancer; 2019 Dec; 27(12):4753-4762. PubMed ID: 30972646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx).
    Cheng HL; Molassiotis A
    Asia Pac J Clin Oncol; 2019 Feb; 15(1):56-62. PubMed ID: 29873180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy.
    Cheng HL; Lopez V; Lam SC; Leung AKT; Li YC; Wong KH; Au JSK; Sundar R; Chan A; De Ng TR; Suen LKP; Chan CW; Yorke J; Molassiotis A
    Health Qual Life Outcomes; 2020 Jul; 18(1):246. PubMed ID: 32703223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes.
    Li T; Timmins HC; Trinh T; Mizrahi D; Harrison M; Horvath LG; Grimison P; Friedlander M; Kiernan MC; King MT; Rutherford C; Goldstein D; Park SB
    J Natl Compr Canc Netw; 2023 Feb; 21(2):125-132.e3. PubMed ID: 36791763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity.
    Alberti P; Bernasconi DP; Cornblath DR; Merkies ISJ; Park SB; Velasco R; Bruna J; Psimaras D; Koeppen S; Pace A; Dorsey SG; Argyriou AA; Kalofonos HP; Briani C; Schenone A; Faber CG; Mazzeo A; Grisold W; Valsecchi M; Cavaletti G;
    Neurology; 2021 Aug; 97(7):e660-e672. PubMed ID: 34078718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reference data of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Questionnaire in the general Dutch population.
    Mols F; van de Poll-Franse LV; Vreugdenhil G; Beijers AJ; Kieffer JM; Aaronson NK; Husson O
    Eur J Cancer; 2016 Dec; 69():28-38. PubMed ID: 27814471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychometric evaluation of the Arabic Version the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20).
    Abu Sharour L
    Appl Neuropsychol Adult; 2021; 28(5):614-618. PubMed ID: 31612735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electronic versus paper-pencil methods for assessing chemotherapy-induced peripheral neuropathy.
    Knoerl R; Gray E; Stricker C; Mitchell SA; Kippe K; Smith G; Dudley WN; Lavoie Smith EM
    Support Care Cancer; 2017 Nov; 25(11):3437-3446. PubMed ID: 28577231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reliability and Validity of the EORTC QLQ-CIPN20 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale) among Thai Women with Breast Cancer Undergoing Taxane-Based Chemotherapy.
    Rattanakrong N; Thipprasopchock S; Siriphorn A; Boonyong S
    Asian Pac J Cancer Prev; 2022 May; 23(5):1547-1553. PubMed ID: 35633537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rasch model-based testing of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) using Alliance for Clinical Trials in Oncology (Alliance) A151408 study data.
    Smith EML; Zanville N; Kanzawa-Lee G; Donohoe C; Bridges C; Loprinzi C; Le-Rademacher J; Yang JJ
    Support Care Cancer; 2019 Jul; 27(7):2599-2608. PubMed ID: 30460399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials.
    Le-Rademacher J; Kanwar R; Seisler D; Pachman DR; Qin R; Abyzov A; Ruddy KJ; Banck MS; Lavoie Smith EM; Dorsey SG; Aaronson NK; Sloan J; Loprinzi CL; Beutler AS
    Support Care Cancer; 2017 Nov; 25(11):3537-3544. PubMed ID: 28634656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire.
    Lavoie Smith EM; Barton DL; Qin R; Steen PD; Aaronson NK; Loprinzi CL
    Qual Life Res; 2013 Dec; 22(10):2787-99. PubMed ID: 23543373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin.
    Alberti P; Rossi E; Cornblath DR; Merkies IS; Postma TJ; Frigeni B; Bruna J; Velasco R; Argyriou AA; Kalofonos HP; Psimaras D; Ricard D; Pace A; Galiè E; Briani C; Dalla Torre C; Faber CG; Lalisang RI; Boogerd W; Brandsma D; Koeppen S; Hense J; Storey D; Kerrigan S; Schenone A; Fabbri S; Valsecchi MG; Cavaletti G;
    Ann Oncol; 2014 Jan; 25(1):257-64. PubMed ID: 24256846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal clinically important differences in the EORTC QLQ-BM22 and EORTC QLQ-C15-PAL modules in patients with bone metastases undergoing palliative radiotherapy.
    Raman S; Ding K; Chow E; Meyer RM; Nabid A; Chabot P; Coulombe G; Ahmed S; Kuk J; Dar AR; Mahmud A; Fairchild A; Wilson CF; Wu JSY; Dennis K; DeAngelis C; Wong RKS; Zhu L; Brundage M
    Qual Life Res; 2016 Oct; 25(10):2535-2541. PubMed ID: 27138964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy.
    Calhoun EA; Welshman EE; Chang CH; Lurain JR; Fishman DA; Hunt TL; Cella D
    Int J Gynecol Cancer; 2003; 13(6):741-8. PubMed ID: 14675309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validity of Patient-Reported Outcome Measures in Evaluating Nerve Damage Following Chemotherapy.
    Li T; Timmins HC; Mahfouz FM; Trinh T; Mizrahi D; Horvath LG; Harrison M; Grimison P; Friedlander M; Marx G; Boyle F; Wyld D; Henderson R; King T; Baron-Hay S; Kiernan MC; Rutherford C; Goldstein D; Park SB
    JAMA Netw Open; 2024 Aug; 7(8):e2424139. PubMed ID: 39120903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal clinically important difference (MCID) for the functional assessment of cancer therapy: cognitive function (FACT-Cog) in breast cancer patients.
    Cheung YT; Foo YL; Shwe M; Tan YP; Fan G; Yong WS; Madhukumar P; Ooi WS; Chay WY; Dent RA; Ang SF; Lo SK; Yap YS; Ng R; Chan A
    J Clin Epidemiol; 2014 Jul; 67(7):811-20. PubMed ID: 24656406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal clinically important differences in the EORTC QLQ-C30 and brief pain inventory in patients undergoing re-irradiation for painful bone metastases.
    Raman S; Ding K; Chow E; Meyer RM; van der Linden YM; Roos D; Hartsell WF; Hoskin P; Wu JSY; Nabid A; Haas R; Wiggenraad R; Babington S; Demas WF; Wilson CF; Wong RKS; Zhu L; Brundage M
    Qual Life Res; 2018 Apr; 27(4):1089-1098. PubMed ID: 29188483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychometric Testing of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale Using Pooled Chemotherapy-Induced Peripheral Neuropathy Outcome Measures Standardization and Alliance for Clinical Trials in Oncology A151408 Study Data.
    Smith EML; Banerjee T; Yang JJ; Bridges CM; Alberti P; Sloan JA; Loprinzi C
    Cancer Nurs; 2019; 42(3):179-189. PubMed ID: 29649081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice.
    Beijers AJ; Vreugdenhil G; Oerlemans S; Eurelings M; Minnema MC; Eeltink CM; van de Poll-Franse LV; Mols F
    Support Care Cancer; 2016 Jun; 24(6):2411-20. PubMed ID: 26634561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.